S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
The Safest Option in Trades! (Ad)pixel
EV Battery Maker Freyr Set For Major Global Expansion
Russia accused of 'kidnapping' head of Ukraine nuclear plant
In 20 years, this little-known trader didn’t have a single losing year…  (Ad)pixel
How major US stock indexes fared Friday 9/30/2022
Putin accuses the West of sabotaging Baltic Sea pipelines
The Collapse of 2022 Has Begun (Ad)pixel
West rejects Putin's claim it sabotaged Baltic gas pipelines
MarketBeat: Week in Review 9/26 – 9/30
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
The Safest Option in Trades! (Ad)pixel
EV Battery Maker Freyr Set For Major Global Expansion
Russia accused of 'kidnapping' head of Ukraine nuclear plant
In 20 years, this little-known trader didn’t have a single losing year…  (Ad)pixel
How major US stock indexes fared Friday 9/30/2022
Putin accuses the West of sabotaging Baltic Sea pipelines
The Collapse of 2022 Has Begun (Ad)pixel
West rejects Putin's claim it sabotaged Baltic gas pipelines
MarketBeat: Week in Review 9/26 – 9/30
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
The Safest Option in Trades! (Ad)pixel
EV Battery Maker Freyr Set For Major Global Expansion
Russia accused of 'kidnapping' head of Ukraine nuclear plant
In 20 years, this little-known trader didn’t have a single losing year…  (Ad)pixel
How major US stock indexes fared Friday 9/30/2022
Putin accuses the West of sabotaging Baltic Sea pipelines
The Collapse of 2022 Has Begun (Ad)pixel
West rejects Putin's claim it sabotaged Baltic gas pipelines
MarketBeat: Week in Review 9/26 – 9/30
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Want to Increase Your Conversion Rates? This Is the Biggest Threat to Your Success.
The Safest Option in Trades! (Ad)pixel
EV Battery Maker Freyr Set For Major Global Expansion
Russia accused of 'kidnapping' head of Ukraine nuclear plant
In 20 years, this little-known trader didn’t have a single losing year…  (Ad)pixel
How major US stock indexes fared Friday 9/30/2022
Putin accuses the West of sabotaging Baltic Sea pipelines
The Collapse of 2022 Has Begun (Ad)pixel
West rejects Putin's claim it sabotaged Baltic gas pipelines
MarketBeat: Week in Review 9/26 – 9/30
NASDAQ:OPGN

OpGen - OPGN Stock Forecast, Price & News

$0.29
-0.09 (-23.92%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.27
$0.36
50-Day Range
$0.29
$0.63
52-Week Range
$0.27
$3.55
Volume
1.45 million shs
Average Volume
202,940 shs
Market Capitalization
$13.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.13

OpGen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
642.5% Upside
$2.13 Price Target
Short Interest
Healthy
0.60% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.91mentions of OpGen in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.55) to ($0.43) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

650th out of 1,093 stocks

Medical Laboratories Industry

19th out of 30 stocks

OPGN stock logo

About OpGen (NASDAQ:OPGN) Stock

OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. The company utilizes molecular diagnostics and informatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.

Receive OPGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OpGen and its competitors with MarketBeat's FREE daily newsletter.

OPGN Stock News Headlines

OpGen Announces $3.38 Million Registered Direct Offering
OpGen (NASDAQ:OPGN) Coverage Initiated by Analysts at StockNews.com
OpGen Q2 2022 Earnings Preview - Seeking Alpha
See More Headlines
Receive OPGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OpGen and its competitors with MarketBeat's FREE daily newsletter.

OPGN Company Calendar

Last Earnings
8/11/2022
Today
10/01/2022
Next Earnings (Estimated)
11/10/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OPGN
Employees
91
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.13
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$1.25
Forecasted Upside/Downside
+642.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
2 Analysts

Profitability

Net Income
$-34,810,000.00
Net Margins
-624.26%
Pretax Margin
-620.87%

Debt

Sales & Book Value

Annual Sales
$4.31 million
Book Value
$1.06 per share

Miscellaneous

Free Float
47,457,000
Market Cap
$13.83 million
Optionable
Not Optionable
Beta
-0.37

Key Executives

  • Dr. Oliver Schacht Ph.D. (Age 51)
    CEO, Pres & Director
    Comp: $600.2k
  • Mr. Johannes BacherMr. Johannes Bacher (Age 53)
    Chief Operating Officer
    Comp: $396.52k
  • Mr. Albert Weber (Age 59)
    CFO & Corp. Sec.
  • Mr. Vadim Sapiro (Age 51)
    Chief Information Officer
  • Mr. Michael Farmer
    VP of Marketing
  • Ms. Faranak Atrzadeh
    Chief Marketing & Scientific Affairs Officer
  • Dr. G. Terrance Walker Ph.D. (Age 63)
    Sr. VP of R&D
  • Mr. Derek Joesting
    Sr. VP of US Sales
  • Dr. Arne Materna
    MD & CEO of Ares Genetics GmbH













OPGN Stock - Frequently Asked Questions

Should I buy or sell OpGen stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OpGen in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" OPGN shares.
View OPGN analyst ratings
or view top-rated stocks.

What is OpGen's stock price forecast for 2022?

2 brokerages have issued twelve-month price objectives for OpGen's stock. Their OPGN share price forecasts range from $1.25 to $3.00. On average, they predict the company's stock price to reach $2.13 in the next twelve months. This suggests a possible upside of 642.5% from the stock's current price.
View analysts price targets for OPGN
or view top-rated stocks among Wall Street analysts.

How have OPGN shares performed in 2022?

OpGen's stock was trading at $1.00 at the start of the year. Since then, OPGN stock has decreased by 71.4% and is now trading at $0.2862.
View the best growth stocks for 2022 here
.

When is OpGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 10th 2022.
View our OPGN earnings forecast
.

How were OpGen's earnings last quarter?

OpGen, Inc. (NASDAQ:OPGN) posted its quarterly earnings data on Thursday, August, 11th. The medical research company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.02. The medical research company had revenue of $0.97 million for the quarter, compared to analyst estimates of $1 million. OpGen had a negative trailing twelve-month return on equity of 75.61% and a negative net margin of 624.26%.

When did OpGen's stock split?

OpGen shares reverse split on the morning of Friday, January 19th 2018. The 1-25 reverse split was announced on Wednesday, January 17th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 18th 2018. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What guidance has OpGen issued on next quarter's earnings?

OpGen issued an update on its second quarter 2022 earnings guidance on Friday, July, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.00 million-$1.00 million, compared to the consensus revenue estimate of $950.00K.

What other stocks do shareholders of OpGen own?
When did OpGen IPO?

(OPGN) raised $17 million in an IPO on Tuesday, May 5th 2015. The company issued 2,900,000 shares at $5.50-$6.50 per share. Maxim Group served as the underwriter for the IPO and National Securities was co-manager.

What is OpGen's stock symbol?

OpGen trades on the NASDAQ under the ticker symbol "OPGN."

How do I buy shares of OpGen?

Shares of OPGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OpGen's stock price today?

One share of OPGN stock can currently be purchased for approximately $0.29.

How much money does OpGen make?

OpGen (NASDAQ:OPGN) has a market capitalization of $13.83 million and generates $4.31 million in revenue each year. The medical research company earns $-34,810,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis.

How can I contact OpGen?

OpGen's mailing address is 708 QUINCE ORCHARD ROAD SUITE 205, GAITHERSBURG MD, 20878. The official website for the company is www.opgen.com. The medical research company can be reached via phone at (240) 813-1260, via email at investorrelations@opgen.com, or via fax at 301-869-9684.

This page (NASDAQ:OPGN) was last updated on 10/1/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.